114 related articles for article (PubMed ID: 12195366)
1. Preemptive therapy for cytomegalovirus infections and the development of resistance to ganciclovir.
Kroes AC; Kalpoe JS
J Infect Dis; 2002 Sep; 186(5):724-5; author reply 725-6. PubMed ID: 12195366
[No Abstract] [Full Text] [Related]
2. Ganciclovir-resistant cytomegalovirus disease in heart transplant recipients: the dilemma of donor-positive/recipient-negative serostatus.
Avery RK
Clin Infect Dis; 2007 Aug; 45(4):448-9. PubMed ID: 17638192
[No Abstract] [Full Text] [Related]
3. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients.
Mattes FM; Hainsworth EG; Geretti AM; Nebbia G; Prentice G; Potter M; Burroughs AK; Sweny P; Hassan-Walker AF; Okwuadi S; Sabin C; Amooty G; Brown VS; Grace SC; Emery VC; Griffiths PD
J Infect Dis; 2004 Apr; 189(8):1355-61. PubMed ID: 15073671
[TBL] [Abstract][Full Text] [Related]
4. Ganciclovir use during mild renal failure in heart transplantation.
Bastien O; Boulieu R; Bleyzac N; Boissonnat P; Garre JP; Dureau G
Transplant Proc; 1996 Oct; 28(5):2876-7. PubMed ID: 8908106
[No Abstract] [Full Text] [Related]
5. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know.
Meylan PR; Pascual M
Clin Infect Dis; 2006 Oct; 43(7):881-3. PubMed ID: 16941369
[No Abstract] [Full Text] [Related]
6. Cytomegalovirus (CMV) resistance to antivirals.
Drew WL; Paya CV; Emery V
Am J Transplant; 2001 Nov; 1(4):307-12. PubMed ID: 12099372
[TBL] [Abstract][Full Text] [Related]
7. Preemptive therapy with intravenous ganciclovir for the prevention of cytomegalovirus disease in lung transplant recipients.
Monforte V; Román A; Gavaldà J; Bravo C; Gispert P; Pahissa A; Morell F
Transplant Proc; 2005 Nov; 37(9):4039-42. PubMed ID: 16386621
[TBL] [Abstract][Full Text] [Related]
8. Extended ganciclovir prophylaxis in lung transplantation.
Perreas KG; McNeil K; Charman S; Sharples LD; Wreghitt T; Wallwork J
J Heart Lung Transplant; 2005 May; 24(5):583-7. PubMed ID: 15896756
[TBL] [Abstract][Full Text] [Related]
9. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
Reddy AJ; Zaas AK; Hanson KE; Palmer SM
J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
[TBL] [Abstract][Full Text] [Related]
10. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation.
West P; Schmiedeskamp M; Neeley H; Oberholzer J; Benedetti E; Kaplan B
Transpl Infect Dis; 2008 Apr; 10(2):129-32. PubMed ID: 17605740
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
Winston DJ; Yeager AM; Chandrasekar PH; Snydman DR; Petersen FB; Territo MC;
Clin Infect Dis; 2003 Mar; 36(6):749-58. PubMed ID: 12627359
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
13. Viral monitoring and successful treatment of a ganciclovir-resistant cytomegalovirus infection in a heart transplant recipient.
García-Martínez J; Folgueira L; Delgado R; Hernando S; Prieto C; Aguado JM; Otero JR
Transpl Infect Dis; 2008 Apr; 10(2):123-8. PubMed ID: 17605746
[TBL] [Abstract][Full Text] [Related]
14. Repopulation of ganciclovir-resistant cytomegalovirus by wild-type virus.
Drew WL; Liu C
Clin Transplant; 2012; 26(6):949-52. PubMed ID: 22774759
[TBL] [Abstract][Full Text] [Related]
15. Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis.
Battiwalla M; Wu Y; Bajwa RP; Radovic M; Almyroudis NG; Segal BH; Wallace PK; Nakamura R; Padmanabhan S; Hahn T; McCarthy PL
Biol Blood Marrow Transplant; 2007 Jul; 13(7):765-70. PubMed ID: 17580254
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir.
Razonable RR; van Cruijsen H; Brown RA; Wilson JA; Harmsen WS; Wiesner RH; Smith TF; Paya CV
J Infect Dis; 2003 Jun; 187(11):1801-8. PubMed ID: 12751039
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation.
Gerna G; Lilleri D; Callegaro A; Goglio A; Cortese S; Stroppa P; Torre G
Transplantation; 2008 Jul; 86(1):163-6. PubMed ID: 18622294
[TBL] [Abstract][Full Text] [Related]
18. Ganciclovir for cytomegalovirus infection.
Am Fam Physician; 1996 Mar; 53(4):1441. PubMed ID: 8629579
[No Abstract] [Full Text] [Related]
19. Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients.
Casillo R; Grimaldi M; Ragone E; Maiello C; Marra C; De Santo L; Amarelli C; Romano G; Della Corte A; Portella G; Tripodi MF; Fortunato R; Cotrufo M; Utili R
Transplant Proc; 2004 Apr; 36(3):651-3. PubMed ID: 15110622
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges.
Puius YA; Snydman DR
Curr Opin Infect Dis; 2007 Aug; 20(4):419-24. PubMed ID: 17609603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
